Albazzaz M K, Patel K R
Department of Respiratory Medicine, Western Infirmary, Glasgow.
Thorax. 1988 Apr;43(4):306-11. doi: 10.1136/thx.43.4.306.
Azelastine, a new oral agent with antiallergic and antihistamine properties, has been shown to inhibit the effect of histamine and leukotriene (LT) in vitro, though not a specific leukotriene receptor antagonist. The effect of both a single dose (8.8 mg) and 14 days' treatment (8.8 mg twice daily) with azelastine on bronchoconstriction induced by LTC4 and histamine has been examined in 10 patients with mild asthma in a placebo controlled, double blind, crossover study. LTC4 and histamine were inhaled in doubling concentrations from a dosimeter and the results expressed as the cumulative dose (PD) producing a 20% fall in FEV1 (PD20FEV1) and 35% fall in specific airways conductance (PD35sGaw). The single dose of azelastine produced a significantly greater FEV1 and sGaw values than placebo at 3 hours, but this bronchodilator effect was not present after 14 days of treatment. Azelastine was an effective H1 antagonist; after a single dose and 14 days' treatment with placebo the geometric mean PD20FEV1 histamine values (mumol) were 0.52 (95% confidence interval 0.14-1.83) and 0.54 (0.12-2.38), compared with 22.9 (11.5-38.3) and 15.2 (6.47-35.6) after azelastine (p less than 0.01 for both). LTC4 was on average 1000 times more potent than histamine in inducing bronchoconstriction. Azelastine did not inhibit the effect of inhaled LTC4; the geometric mean PD20FEV1 LTC4 (nmol) after a single dose and 14 days' treatment was 0.60 and 0.59 with placebo compared with 0.65 and 0.75 with azelastine. The PD35sGaw LTC4 was also unchanged at 0.66 and 0.73 for placebo compared with 0.83 and 0.74 for azelastine. Thus prolonged blockade of H1 receptors did not attenuate the response to LTC4, suggesting that histamine and LTC4 act on bronchial smooth muscle through different receptors. Four patients complained of drowsiness while taking azelastine but only one who was taking placebo and three patients complained of a bitter, metallic taste while taking azelastine.
氮卓斯汀是一种具有抗过敏和抗组胺特性的新型口服药物,尽管它不是一种特异性白三烯受体拮抗剂,但已证实在体外可抑制组胺和白三烯(LT)的作用。在一项安慰剂对照、双盲、交叉研究中,对10例轻度哮喘患者研究了单剂量(8.8毫克)和14天治疗(每日两次,每次8.8毫克)氮卓斯汀对LTC4和组胺诱导的支气管收缩的影响。从剂量仪中以成倍增加的浓度吸入LTC4和组胺,结果以产生FEV1下降20%(PD20FEV1)和特定气道传导率下降35%(PD35sGaw)的累积剂量(PD)表示。单剂量氮卓斯汀在3小时时产生的FEV1和sGaw值显著高于安慰剂,但治疗14天后这种支气管扩张作用消失。氮卓斯汀是一种有效的H1拮抗剂;单剂量和14天安慰剂治疗后,组胺的几何平均PD20FEV1值(微摩尔)分别为0.52(95%置信区间0.14 - 1.83)和0.54(0.12 - 2.38),而氮卓斯汀治疗后分别为22.9(11.5 - 38.3)和15.2(6.47 - 35.6)(两者p均小于0.01)。LTC4诱导支气管收缩的效力平均比组胺强1000倍。氮卓斯汀不抑制吸入LTC4的作用;单剂量和14天治疗后,安慰剂组LTC4的几何平均PD20FEV1(纳摩尔)为0.60和0.59,氮卓斯汀组为0.65和0.75。安慰剂组的PD35sGaw LTC4也无变化,分别为0.66和0.73,氮卓斯汀组为0.83和0.74。因此,长期阻断H1受体并未减弱对LTC4的反应,这表明组胺和LTC4通过不同受体作用于支气管平滑肌。4例患者在服用氮卓斯汀时抱怨嗜睡,但服用安慰剂的只有1例,3例患者在服用氮卓斯汀时抱怨有苦味和金属味。